The acquired brands include AntaGolin, RyChol, NeuroVance, SkinVance, FlamLeve, Rheumalin, SleepVance, ImmunoVance, and OviVance, it added.
These products cater to a range of health issues such as metabolic syndrome, insulin resistance, cognitive function, skin health, inflammation, joint care, sleep quality, immune support, and women’s hormonal well-being.
“This acquisition is a major step for Lupin to expand our footprint in the complementary and alternative medicines sector,” Lupin President EMEA Thierry Volle said.
MNI’s innovative plant-based products align perfectly with company’s goal to provide holistic and sustainable healthcare solutions to patients in South Africa, he added. Lupin shares on Friday ended 0.65 per cent up at Rs 2,197.60 apiece on the BSE.